Physician profile
Khalid Baig
NPI 1720199342
$5,550.13
in general payments reported to CMS, 2019-2025
31 companies · $613 in 2025
The $613 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $711 · 2021: $1,033 · 2022: $1,266 · 2023: $578 · 2024: $1,019 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,211.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,128.35 | 2020-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $589.90 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $415.95 | 2019-2022 | |
| Abbvie INC. | $400.99 | 2021-2024 | Vraylar, Ubrelvy |
| Pfizer INC. | $396.53 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.34 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $308.14 | 2020-2024 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $308.00 | 2021-2025 | |
| Lilly USA, LLC | $279.19 | 2019-2025 | Jardiance |
| Amgen INC. | $223.60 | 2024-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $142.82 | 2019-2024 | |
| Glaxosmithkline, LLC. | $141.55 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Allergan, INC. | $90.83 | 2019-2020 | |
| Mylan Specialty L.P. | $89.83 | 2021-2022 | |
| Electromed, INC. | $85.41 | 2024 | Smartvest |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $77.97 | 2022-2023 | Dexcom G6 Transmitter |
| Mallinckrodt Hospital Products INC. | $75.75 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $67.19 | 2022 | |
| Xeris Pharmaceuticals, INC. | $63.19 | 2022-2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $57.16 | 2024 | Uzedy, Austedo Xr |
| Genentech USA, INC. | $41.48 | 2020 | |
| Merck Sharp & Dohme LLC | $39.80 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $38.20 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $36.43 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $25.02 | 2021 | |
| Boston Scientific Corporation | $24.10 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $21.77 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.07 | 2019 | |
| Exact Sciences Corporation | $18.73 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.84 | 2021 | |
| Abbott Laboratories | $16.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.